Patent Application
20230371887
The present invention relates to a monitoring and evaluation method of muscle hemodynamic performance, in particular a monitoring and evaluation method based on the use of near infrared sensors (NIRS).
The object of the present invention is to provide a method and a muscle hemodynamic monitoring and evaluation system that allows to evaluate and analyze the performance of muscle tissues in an analytical way and a global way overall performance of all muscle tissues during a cyclical locomotor activity.
Nowadays, a lot of many assessment methods and devices, both invasive and non-invasive, are used to assess the physiological performance of the human body in a multitude of locomotor movements and in a wide variety of conditions. One of the most used methods to evaluate the physiological performance during exercise is the measurement of indirect calorimetry, from which derive variables relating to the exchange of gases in the human body.
Indirect calorimetry is a representation of the joint performance of all muscle tissues. On the other hand, this evaluation method doesn't allow to know what the performance of each one of the muscular tissues has been like.
Blood Lactate [La +] measurements are also widely very used in the research and sports world to correlate them with locomotor performance, since certain levels and increases in Blood Lactate values are associated with certain work intensities.
The closest method that allows to partially measure the performance of the muscular tissues during a Locomotor Activity or Cyclic Physical Activity (AFM) is the use of electromyography, whether invasive or surface. However, this method only allows obtaining the electrical activation values of each muscle tissue (TM).
Currently athletes and coaches use one to three NIRS devices to evaluate the physiological performance of an athlete in a physical activity. In these studies, only Muscular Oxygen Saturation (SmO2) and Capillary Hemoglobin (ThB) values are used to establish in a very generic way what the athlete's performance limitation has been during exercise. Thus, the data obtained from one or two muscle tissues are used to determine that the subject evaluated has a general physiological limitation of this nature in his muscles, without taking into account the performance of other muscle tissues.
Likewise, state-of-the-art studies use only 1 or 2 NIRS devices to evaluate highly analytical aspects of the hemodynamic performance (% SmO2, ThB, O2HHb, HHb) of one or two muscle tissues (mainly: deltoid, vast lateral & rectus femoris). Data obtained from muscle tissues are used to represent the hemodynamic performance of all muscle tissues, assuming that there is symmetry in all active tissues.
The present invention refers to a method of monitoring and evaluating of muscle hemodynamic performance, in a non-invasive way, through the use of near-infrared spectroscopy (NIRS) devices, to establish the hemodynamic performance of multiple muscles tissues (TMs) of simultaneously during a Locomotor Activity or Cyclic Physical Activity (AFM) determined.
In general, the monitoring and evaluation method of the invention analyses three aspects of muscle hemodynamic performance which are:
Each one of these aspects determine the general hemodynamic performance of each muscle tissue and at the same time report a collective performance of the muscular system as a whole. Oxidative capacity and blood delivery have a series of sub-factors that determine specific aspects of their activity, offering information on the level of performance of each TM individually and collectively, in addition to the link with other physiological systems.
The method of the invention comprises in general the following differentiated parts:
The invention refers to a Muscle Hemodynamic Monitoring and Evaluation Method that allows the evaluation and analysis of locomotor performance during AFCM, allowing to analysis and determination of the systemic or analytical physiological factors that limit or impede the perfect locomotor performance of human muscle tissues.
In the first place, data capture is carried out, which refers to procedures prior to data recording of the evaluation and monitoring method of the invention.
The AFMM comprises one or more of the following characteristics:
The processing system takes care of the data management stage, which includes downloading, synchronization, data filtering, and data analysis.
Thus, once the AFCM is finished, the following steps will be carried out:
% (SmO2)*g/dL (ThB)=g/dL (O2HHb)
g/dL (ThB)−g/dL (O2HHb)=g/dL (HHb)
[g/dL (ThB)*(HR)]/60=g/dL/seg (ϕThB)
[g/dL (O2HHb)*(HR)]/60=g/dL/seg (ϕO2HHb)
[g/dL (HHb)*(HR)]/60=g/dL/seg (ϕHHb)
Then, through the processing system, an analysis and an evaluation of the data obtained during the AFCM is carried out.
Previously to the analysis of the physiological factors, the intensity or range of locomotor intensity equivalent to the Minimum Activation Threshold (UAmin), the Aerobic Threshold (UAe) and the Anaerobic Threshold (UAna) that the user has developed during the AFCM will be established.
To be able to establish each of the thresholds mentioned, it will require that intensities above these thresholds have been developed in the AFCM, in order to be monitored.
Previous calculating the physiological thresholds, the trend line of each value obtained and/or calculated, for each TMM will be established.
Thus, it proceeds to perform, through the processing system, an analysis and evaluation of physiological thresholds and the calculation of a trend line of the values obtained.
To the Physiological Thresholds are obtaining from combination of all the data of SmO2%, ThB, ϕThB, O2HHb, ϕO2HHb, HHb, ϕHHb of all TMM. The procedure for calculating the Thresholds, through the processing system, has got the following steps:
Procedure A
Procedure B
Procedure C
To set whether a set of values |Y|SmO2%, |Y|ThB, |Y|ϕThB, |Y|O2HHb, |Y|2ϕO2HHb, |Y|HHb and/or |Y|ϕHHb, between two INTTL or two R-INTTL, of at least two TMSM have some level of symmetry or asymmetry, the following procedure must be carried out:
B) Symmetry Coefficient Between the Trends of the Values—TGV ()
To establish whether the trend of the values |Y|SmO2%, |Y|O2HHb, |Y|ϕO2HHb, |Y|HHb and/or |Y|ϕHHb, between two INTTL or two R-INTTL determined, of a TMM have some level of symmetry or asymmetry with the trend of the values |Y|SmO2%, |Y|O2HHb, |Y|ϕO2HHb, |Y|HHb and/or |Y|ϕHHb, between two INTTL or two R-INTTL determined, of at least one other TMM or a set of TMSM, the following procedure must be carried out:
=[
|Y|]−[
|Y|]
A. Muscle Oxidative Capacity
The oxidative capacity is the potential of the muscular tissues to consume the oxygen delivered in the muscular capillaries and with the objective of producing an amount of adenosine triphosphate (ATP) necessary for the locomotor movement.
When evaluating the hemodynamic performance, the performance of the global muscle oxidative capacity is established, that is, the global or average level of the entire locomotor system, and at the same time the individual performance level of each muscle tissue is established. Since there are multiple factors that can affect to the ability of consume oxygen of only one muscle tissue while the consumption potential remains intact in the other muscle tissues.
A perfect global or general muscle oxidative capacity occurs when each muscle tissue that participates in locomotor activity is capable of consuming all the oxygen delivered by the cardiovascular system.
On the contrary, limitations can occur with respect to the maximum potential of oxidative capacity when in at least one, a group or all the muscular tissues do not express the maximum capacity or potential to consume all the oxygen delivered by the cardiovascular system.
Factor (A1) is that factor that analyzes and evaluates the performance of the level of mitochondrial density and/or oxidative enzymes available to muscle tissues. Oxygen is consumed within the mitochondria and the enzymes participate in this process and establish the speed at which it is consumed, a low level of both means a low capacity to consume oxygen and produce high amounts of energy per unit of time. A limitation in this factor means a general limitation of oxidative capacity in practically almost all muscle fibers.
To establish that there is a Limitation in Factor A1, the following steps and criteria must be met:
The functional factor of oxidative capacity is that factor that analyzes and evaluates whether the muscle tissues have the potential or the capacity to consume large amounts of oxygen delivered by the cardiovascular system, but due to factors of general fatigue, the muscle tissues lose part or all its consumption potential. Once the general fatigue disappears, this limitation disappears, it is a temporary limitation of the performance of the oxidative capacity and it is observed in practically all the muscular tissues at the same time.
To establish a Limitation on Factor (A2) the following steps and criteria must be met:
If a second evaluation is carried out after a recovery period where the general fatigue disappears, it could be observed how all the muscular tissues regain their oxygen consumption potential and the asymmetries generated by the general fatigue also disappear and the muscle saturation would return to being symmetric in each muscle tissue compared with his contralateral muscle tissue.
The functional factor of the oxidative capacity due to Muscle Inhibition is that factor that analyzes each muscle tissue individually to assess whether the analyzed muscle tissue loses its potential or the ability to consume large amounts of oxygen temporarily due to a muscle inhibition. This factor is usually observed in isolated tissues, which lose their potential while the rest of the muscle tissues keep their oxygen consumption potential intact, unlike what happens in the functional factor due to general fatigue.
To establish a Limitation on Factor A3, the following steps and criteria must be met:
The Neuromuscular factor of Oxidative Capacity (Intermuscular Coordination) is that factor that analyzes and evaluates whether the muscle tissues have the potential or the ability to consume large amounts of oxygen delivered by the cardiovascular system, but certain evaluated muscle tissues that participate in the activity locomotive, they do not, while the other muscular tissues do develop their potential.
This occurs mainly due to two aspects, the muscle recruitment pattern by the nervous system and, on the other hand, the biomechanical pattern performed by the subject during locomotor movement.
The pattern of muscle recruitment by the nervous system (Intermuscular Coordination) refers to the level of activation and participation in locomotor activity, a perfect muscle recruitment would mean that all the muscle tissues that participate in said movement have the same level of metabolic activation and therefore, the same muscle oxygen consumption. The level of performance of this aspect is determined by the ability of the nervous system to recruit and activate all muscle tissues symmetrically during locomotor movement. When the nervous system is not efficient in muscle recruitment, it activates differently and to a greater or/or lesser degree the different muscle tissues involved in locomotor activity. It should be noted that when this happens, a symmetry is usually observed between muscle tissues and their contralateral muscle tissues in the hemodynamic and activation values. When a lesser degree of recruitment occurs in muscle tissues and its contralateral muscle for the reasons mentioned above, they may present a limitation in oxidative capacity, as they have the potential to consume large amounts of oxygen, but do not develop said potential during locomotor activity due to less nervous activation.
The biomechanical pattern refers to the physical movement carried out by the evaluated subject, any type of incorrect and/or inefficient biomechanical pattern may mean that the nervous system must recruit some muscle tissues to a greater or/or lesser extent than other muscle tissues that participate in locomotor activity to be able to cope with said alterations or inefficient biomechanical patterns.
When a muscle tissue and its contralateral muscle tissue are affected by this factor and their level of nerve activation is reduced, these muscle tissues do not express their maximum potential for oxygen consumption due to low nerve activation
The two previous patterns or factors are the cause of a limitation of the Neuromuscular factor of Oxidative Capacity (Intermuscular Coordination). To establish a Limitation on Factor A4, the following steps and criteria must be met.
B. Oxygen-Loaded Blood Delivery Capacity in the Venous Return
The Capacity to Deliver Oxygen-Loaded Blood Flow and the Venous Return is a performance performed jointly, dependently, harmonically and synchronized by the different vascular, muscular and nervous tissues together with the multiple organs of the body involved in gas exchange, the maintenance of blood pressure, supply and redistribution of oxygen-laden blood flow throughout the body, the level of metabolic activation of each tissue, and venous return during locomotor movement.
To fully analyze and evaluate the performance of Oxygen-Charged Blood Delivery Capacity and Venous Return, the limiting factors for performance are divided according to the physiological system that interacts with some aspect of blood flow. The 3 systems into which the factors are divided are the pulmonary system, the cardiovascular system and the nervous system.
The Structural Factor of the Pulmonary System is that factor that analyzes and evaluates if there is any type of limitation in the exchange of gases produced in the lung, negatively affecting and reducing the delivery of oxygen-charged haemoglobin to the muscle tissues.
The Pulmonary Structural Factor indirectly represents the state and performance of the pulmonary structures involved in gas exchange (for example, the pulmonary alveoli). Any deficiency in these structures can affect to the uptake of oxygen O2 and the expulsion of CO2 and H2O from the bloodstream.
Any limitation related to problems in gas exchange or oxygen uptake is observed mainly in greater delays in terms of post-effort recovery periods and in oxygen replenishment in muscle tissues. In people without any type of alteration in this factor, the recovery or replenishment of oxygen is almost immediately, but in people with a certain limitation of this factor, the delay in replenishment can exceed 10 seconds or even reach half a minute in very evident cases.
This limitation is mainly observed in people with respiratory diseases diagnosed as COPD, people with 1 lung, asthmatics, or smokers generally.
To establish if there is a limitation of the Pulmonary Structural Factor, the following steps must be followed, and the established criteria must be met:
The Pulmonary Functional Factor (Respiratory Muscles) is that factor that analyzes and evaluates if there is any type of limitation in the exchange of gases in the lungs produced by the inefficiency and/or incapacity of the muscular tissues in charge of the biomechanical phases of respiration [inspiration and expiration].
When there is an inefficiency in the performance of these muscle tissues, the maximum potential to introduce the greater volume of oxygen (L/min) into the lungs through negative pressure is reduced, which is generated by the contraction and elevation of the rib cage.
The effects are the same as the Pulmonary System Structural Factor, but with a different limiting cause. The magnitude of the limitation depends on the level of deconditioning or inefficiency of performance by the respiratory muscle tissues. Even any muscle blockage or “muscle contracture” in muscle tissues that limits the range of motion of the rib cage can prevent the maximum volume of oxygen introduced into the lungs from being generated.
To establish whether there is a limitation of the Pulmonary Functional Factor, the following steps must be followed and the established criteria must be met:
The Performance Factor of Analytical Delivery of Blood Flow during exercise is that factor that analyzes and evaluates cardiovascular performance in each of the muscle tissues that participate in locomotor activity. This factor analyzes how the cardiovascular system satisfies the demands of blood flow from the muscle and determines how the characteristics of the flow delivered to each muscle are.
In many cases, the delivery of blood flow is totally different in each of the muscle tissues, for that reason the characteristics of blood flow are analyzed individually, allowing to identify if there is some type of hierarchy of preference between muscle tissues in terms of the delivery of blood.
In order to evaluate and establish the performance of Factor (B2.1), the following steps must be followed and the established criteria must be met:
||
=(Median of {|Y|1;|Y|2;|Y|3; . . . ,})+(σ{|Y|1;|Y|2;|Y|3; . . . ,})/2
||
=(Median of {|Y|1;|Y|2;|Y|3; . . . ,})−(σ{|Y|1;|Y|2;|Y|3; . . . ,})/2
During exercise, the active muscles contract and vasodilation occurs due to various mechanical, nervous and metabolic factors. If this vasodilation occurs excessively, it can “threaten” the systemic regulation of blood pressure throughout the body, for that reason the sympathetic nervous system does a vascular vasoconstriction to maintain blood pressure and blood flow levels in order to maintain regular oxygen supply to the brain and vital organs (Functional Sympatholysis).
Regulation of blood flow to skeletal muscle is closely linked to metabolic oxygen demand and with a change in oxygen requirement leading to a proportional change in blood flow. The precise control of the regulation of blood flow serves to minimize the work of the heart, while ensuring an adequate supply of oxygen to the working muscles. The need for this precise control of blood flow to the muscle becomes apparent when you consider that active skeletal muscle comprises about ˜40% of body mass and that muscle-specific blood flow can increase nearly 100-fold from rest to intense exercise. Given the limitation in maximum cardiac output, the heart can only supply a fraction of the active muscles with maximum blood flow and during high intensity exercises involving greater muscle mass, vascular conductance has to be well regulated or pressure blood pressure could drop.
This factor evaluates and analyzes the performance of Functional Sympatholysis, that is, the performance of the nervous system on cardiovascular function in the redistribution of blood flow. In order to analyze this factor, rest intervals are used, since once the exercise ceases, the vasoconstrictive effect of the nervous system ceases, but the opposing vasodilator effects at the muscular level remain active as they are slower. This allows to analyze the magnitude of their performance during the exercise that was previously carried out.
In order to evaluate and establish the performance of Factor (B2.2), the following steps must be followed and the established criteria must be met:
When multiple work intervals are performed with their respective rest intervals, the evolution of cardiovascular performance in the delivery/demand of blood flow of a muscle tissue can be evaluated. This factor analyzes the evolution of this performance and for this a comparison is made between the values of the analyzed muscle tissue, in the rest intervals analyzed.
In order to evaluate and establish the performance of Factor (B2.3), the following steps must be followed and the established criteria must be met:
The Muscle Blood Flow Pumping Factor is that factor that analyzes and evaluates the performance of each muscle tissue during locomotor movement to perform muscle contraction and compress the blood vessels located in said muscle tissues. This compression of the blood vessels causes the venous return of blood flow to the heart.
Each muscle tissue must be able to generate sufficient mechanical stress on the blood vessels to drive blood flow through the venous system. The collective performance of this factor is important to maintain efficient venous return.
The cardiovascular system is a closed circuit system, any alteration of the maximum venous return potential affects the entire cardiovascular system, because if the maximum volume of blood that returns to the heart through the venous return decreases, cardiac filling will decrease, then the stroke volume will be lower, and later the arterial pressure will drop, since the volume of blood ejected by the heart will be lower.
To establish a Limitation on Factor (B2.4) in at least one TMM, the following steps and criteria must be met:
The Neuromuscular Activation Factor (Intermuscular Coordination) is that factor that analyzes and evaluates the performance of the nervous system to activate each muscle tissue during locomotor movement. This factor includes the analysis, evaluation and comparison between the different levels of metabolic activation generated by the nervous system between the muscular tissues that participate in locomotor activity (Intermuscular Coordination).
A perfect or efficient neuromuscular activation of all muscle tissues is one in which all muscle tissues involved in locomotor activity have the same level of metabolic activation to cope with the demands of locomotor movement.
When there are multiple levels of activation, an optimal (efficient) activation range is established to be able to assess the activation level of each muscle tissue individually. A muscle tissue that is below or above said optimal activation zone can be interpreted that that tissue has a higher u/or lower muscle activation and therefore the metabolic efficiency of the set of muscle tissues decreases.
A greater symmetry in the levels of muscle activation during locomotor work translates into a lower energy cost to cope with said locomotor work/movement, on the other hand, a greater asymmetry of the whole and/or a muscle tissue means a higher energy cost for cope with locomotor work/movement [Running Economy].
Therefore, there is an individual muscle activation level of each muscle tissue and a global muscle activation of all muscle tissues for each intensity of locomotor work of an evaluated subject, that is, multiple neuromuscular activation factors.
To establish a Factor Performance Level (B3.1) of at least one TMM, the following steps and criteria must be met:
||
=(Mediana de{|Y|1;|Y|2;|Y|3; . . . ,})+(σ{|Y|1;|Y|2;|Y|3; . . . ,})/2
||
=(Mediana de{|Y|1;|Y|2;|Y|3; . . . ,})−(σ{|Y|1;|Y|2;|Y|3; . . . ,})/2
where |Y| is the value (SmO2%, O2HHb or ϕO2HHb) of each TMM, in the determined INTTL or R-INTTL and (σ) the standard deviation of (SmO2%, O2HHb or ϕO2HHb) of each TMM, in the determined INTTL or R-INTTL.
The Neurovascular Structural Factor (Speed and Power of Muscle Contraction) is that factor that analyzes and evaluates the potential of [vasodilation vs vasoconstriction] in each muscle tissue evaluated.
When the action potential is produced in the muscle tissue to produce the muscle contraction necessary for locomotor movement, this nerve potential also has an inhibitory effect and some chain responses that cause an inhibition of the vasoconstrictive effect of the sympathetic nervous system. On the other hand, it causes marked vasodilation in the arteriolar tissues close to the place where the action potential is produced.
Therefore, vasodilation in muscle tissues is directly correlated with the speed of muscle contraction and/or the level of activation of said muscle tissue. Muscle tissue must have an optimal level of vasodilation to allow optimal oxygen-laden blood flow to arrive. Excessive vasodilation may mean that excessively vasodilated muscle tissue receives a greater volume of blood flow, more than is necessary to meet the metabolic oxygen demands that muscle tissue requires. This fact causes an inefficiency in the delivery of oxygen-laden blood flow by not being able to deliver this excess blood flow to other muscle tissues that do require it, causing a deficit in the delivery of oxygen-laden blood flow.
To establish a Limitation on Factor (B3.2) in at least one TMM, the following steps and criteria must be met:
The Muscle Contraction Speed Factor is that factor that analyzes and evaluates the frequency at which muscle contractions occur during locomotor activity.
To produce a muscle contraction, the nervous system produces an electrical impulse that causes alterations in cellular metabolism to generate the contraction of muscle fibers. Said electrical impulse also has an inhibiting effect on the local vasoconstrictor receptors of the arteriolar network of the muscle.
A high production of these impulses produces a high inhibition of vasoconstrictors and consequently increases the vasodilation of the arteries in the TM. At a certain point, an excessive vasodilation produces an excess delivery of blood flow, whereas a low frequency of electrical impulse discharge in the muscle will produce a low vasodilation and a greater vasoconstriction, producing an arterial occlusion mediated by the sympathetic nervous system.
For this reason, this factor is in charge of evaluating muscle performance as a whole to establish which muscle contraction frequency (FCM) or Muscle Contraction Frequency Range (R-FCM) is optimal for the hemodynamic performance of the cardiovascular system.
To evaluate and establish the performance of Factor (B3.3) in the set of TMM, the following steps and criteria must be met:
The method of the invention described is of particular interest in the following practical applications, in which its advantages are evident:
1) Sports and Physical Activity Area
2) Area of Medicine, Physiotherapy, Dietetics and Research:
3) Industrial and Textile Area:
The monitoring method of the invention described makes it possible to evaluate and monitor the muscle hemodynamic performance of all TMSM analytically, globally and both at the same time, during a AFC. This evaluation includes TMSM that are not directly involved in locomotor work, such as the muscular tissues responsible for respiratory movements.
Likewise, the method of the invention allows the generation of an individualized physiological profile, as it offers complete information on the factors that affect or limit the analytical hemodynamic performance of each TMM and, at the same time, the general hemodynamic performance of all TMSM as a whole. Thus establishing, in a very analytical way, the physiological factors that limit the performance of subject.
On the other hand, the method of the invention allows the analysis to be carried out in the training sessions themselves without the need to make any modification of the AFC that the subject is developing, or any specific protocol, or any environmental or environmental conditions. On the contrary, the usual evaluation methods generally require a controlled environment, in laboratories or closed places, moving away from the reality of the AFC developed by the majority of subjects.
The method of the invention also makes it possible to quantify the running economy or efficiency of work of TMSM from an analytical physiological point of view. By analyzing the individual performance of each TMM separately, then jointly with other TMSM, it allows quantifying the running economy or efficiency of work to be able define it, as well as establishing the specific tissues and/or factors that positively affect and/or negatively to the economy of work.
The evaluation methods, up to now, measured and quantified the efficiency of locomotor performance from general values of the whole body such as the analysis of metabolic gases or blood lactate concentrations, or using external variables such as power development values or measurements of strength in exercises. However, with the method of the invention, the performance performed by each of the muscle tissues is directly evaluated and at the same time the global work, allowing to identify the muscle tissues that are negatively affecting the economy of work and, at the same time, evaluate how the performance is being in the set of muscular tissues.
By identifying the factors that negatively affect or limit performance, the method of the invention makes it possible to establish action or training protocols to specifically improve said factors optimally and improve locomotor performance.
Currently, there is no other monitoring method that allows offering analytical and global information on hemodynamic performance in a non-invasive way, with the advantages of the method of the invention.
The invention also refers to a monitoring and evaluation system of the physical performance of a subject comprising:
To complement the description that is being made and in order to help a better understanding of the characteristics of the invention, according to a preferent example of a practical embodiment thereof, a set of drawings is attached as an integral part of said description, in which, for illustrative and non-limiting purposes, the following has been represented:
|Y|SmO2% (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|SmO2% (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|SmO2% (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|SmO2% (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|SmO2% (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|SmO2% (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|SmO2% (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|ThB (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|ϕThB (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|O2HHb (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|HHb (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|ϕO2HHb (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the RF L (1) and RF R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the VL L (1) and VL R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the ST L (1) and ST R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the GM L (1) and GM R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the VI L (1) and VI R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the GA L (1) and GA R (2), and the values of power (Axis X—Watts).
|Y|ϕHHb (Axis Y) of the TA L (1) and TA R (2), and the values of power (Axis X—Watts).
Subject Evaluated
Material Used for the Activity or Monitored Locomotor Exercise
Data Recording Procedures for the Evaluation and Monitoring Method
and
and the
and
between each
ThB
|
|
The following muscle performance factors do not meet the criteria established by each factor to determine that any TMM or all of them develop at least one limitation of said factors:
| Number | Date | Country | Kind |
|---|---|---|---|
| P202030749 | Jul 2020 | ES | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/ES2021/070530 | 7/16/2021 | WO |
